Powder: -20°C for 3 years
In solvent: -80°C for 6 months
Eslicarbazepine acetate (ESL) is an anticonvulsant medication approved for use in Europe, the United States and Canada as an adjunctive therapy for partial-onset seizures that are not adequately controlled with conventional therapy.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
10 mg | In stock | 46.00 | |
25 mg | In stock | 84.00 | |
50 mg | In stock | 126.00 | |
100 mg | In stock | 174.00 | |
200 mg | In stock | 313.00 | |
500 mg | In stock | 414.00 | |
1 mL * 10 mM (in DMSO) | In stock | 50.00 |
Description | Eslicarbazepine acetate (ESL) is an anticonvulsant medication approved for use in Europe, the United States and Canada as an adjunctive therapy for partial-onset seizures that are not adequately controlled with conventional therapy. |
Targets&IC50 | Others |
Synonyms | BIA 2-093 , Zebinix , Exalief , Stedesa , Aptiom |
Purity | 98.00% |
Molecular Weight | 296.32 |
Formula | C17H16N2O3 |
CAS No. | 236395-14-5 |
Powder: -20°C for 3 years
In solvent: -80°C for 6 months
DMSO: 55 mg/mL (185.6 mM)
Ethanol: 9 mg/mL (30.4 mM)
Water: <1 mg/mL
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.